Table 2 Mapped EQ-5D utilities by mapping algorithm, treatment arm, tumour site and progression status
McKenzie algorithm [16] | Longworth algorithm [15] | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Overall | Lanreotide | Placebo | Overall | Lanreotide | Placebo | |||||||
Mean (SE) | Sample size | Mean (SE) | Sample size | Mean (SE) | Sample size | Mean (SE) | Sample size | Mean (SE) | Sample size | Mean (SE) | Sample size | |
All patients | 0.79 (0.01) | 1053 | 0.79 (0.01) | 540 | 0.79 (0.01) | 513 | 0.80 (0.01) | 1041 | 0.80 (0.01) | 530 | 0.80 (0.01) | 511 |
Midgut | 0.77 (0.01) | 412 | 0.79 (0.01) | 193 | 0.76 (0.02) | 219 | 0.79 (0.01) | 407 | 0.80 (0.01) | 192 | 0.78 (0.01) | 215 |
Pancreas | 0.80 (0.01) | 430 | 0.79 (0.02) | 210 | 0.81 (0.01) | 220 | 0.80 (0.01) | 426 | 0.80 (0.01) | 204 | 0.80 (0.01) | 222 |
Stable disease | 0.79 (0.01) | 997 | 0.79 (0.01) | 522 | 0.79 (0.01) | 475 | 0.80 (0.01) | 986 | 0.80 (0.01) | 513 | 0.80 (0.01) | 473 |
Progressive disease | 0.72 (0.04) | 56 | 0.77 (0.05) | 18 | 0.70 (0.04) | 38 | 0.75 (0.02) | 55 | 0.78 (0.04) | 17 | 0.74 (0.03) | 38 |
Utility decrement | −0.07 | −0.02 | −0.10 | −0.05 | −0.02 | −0.06 | ||||||